Unrelenting EBM
Kuma FolmsbeeMy personal Substack. Generative AI is not used for any of the writing (including content, grammar or prose)
| Platform |  | Pricing | Only free issues | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 105 | Founded | 2 years ago | Last Issue | 8 days ago |
| Active | |||||
Read this Newsletter
unrelentingebm.substack.comLatest Issues
Are Glp1a life long medications?
Horn, D. B., Aronne, L. J., Wharton, S., Bays, H. E., le Roux, C. W., Srinath, R., Gomez-Valderas, E., Arad, A. D., Das, S., Dunn, J. P., Ribeiro, A., Glass, L. C., & Lee, C. J. (2026). Tirzepatide for maintenance of bodyweight reduction in...
Delayed development of glp-1a
Drug Development Failure: How GLP-1 Development was abandoned in 1990. Jeffrey S. Flier. Perspectives in Biology and Medicine.
The recap–Dr. Flier was part of a group that worked on a GLP-1a in 1990 when it was shown to lower sugar levels...
Don’t call it a comeback (Digoxin for HFrEF)
Damman K, van Veldhuisen DJ, Bauersachs J, et al. Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis. JAMA. Published online May 10, 2026
The above paper was a meta-analysis of studies looking at digitalis glycos...
Week 205 - AI “defeats” ED docs?
Brodeur, P. G., Buckley, T. A., Kanjee, Z., Goh, E., Ling, E. B., Jain, P., Cabral, S., Abdulnour, R.-E., Haimovich, A. D., Freed, J. A., Olson, A., Morgan, D. J., Hom, J., Gallo, R., McCoy, L. G., Mombini, H., Lucas, C., Fotoohi, M., Gwiaz...
A lot of LDL reduction for a little morbidity reduction (VESALIUS)
Marston NA, Bohula EA, Bhatia AK, et al. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. JAMA. 2026;335(16):1400-1407. doi:1...
Key Facts
Audience Metrics
Subscribers, engagement, traffic and sponsorship for Unrelenting EBM.
| Subscribers | Engagement | 65 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Explore More
Authors
The writers behind this newsletter.
Internist figuring out critical appraisal. Mostly done for myself but anyone else welcome.
Frequently Asked Questions
How can I access the email archive for Unrelenting EBM?
You can find recent issues that have been published by Unrelenting EBM on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Unrelenting EBM have?
To see how many people subscribe to Unrelenting EBM, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Unrelenting EBM?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Unrelenting EBM as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Unrelenting EBM?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Unrelenting EBM using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to Unrelenting EBM?
Scroll up to where it says Related Newsletters to see other publications like Unrelenting EBM. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Unrelenting EBM?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.